© 2020 MJH Life Sciences and OncLive. All rights reserved.
June 24, 2014
Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.
June 27, 2012
Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel